Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Positron Corporation

Market Cap 58.8M 50.68M 46.64M 43.76M 82.19M 5.56B 83.01M 551M 215M 2.72B 221M 216M 9.42B P/E Ratio 2024
-11x
P/E Ratio 2025 -4.87x
Enterprise Value 57.66M 49.7M 45.74M 42.91M 80.6M 5.45B 81.41M 541M 211M 2.67B 216M 212M 9.23B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
47.44%
Yield 2024 *
-
Yield 2025 -
1 week-5.29%
Current month-4.79%
1 month-7.97%
3 months-14.07%
6 months+28.78%
Current year+7.19%
1 week 1.76
Extreme 1.76
1.84
1 month 1.7
Extreme 1.7
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.29%+14.01%+2.29% 58.8M
-0.67%-1.26%-12.54%-18.16% 13.82B
+3.66%-1.74%+82.94%+13.94% 4.89B
-0.10%+2.07%-39.02%-64.77% 1.25B
+2.59%-1.25%-31.82%-42.27% 1.2B
-3.00%-3.81%+56.08%+81.25% 1.2B
-0.64%+2.79%-40.95% - 985M
+0.54%-1.41%+194.20%+194.35% 716M
+0.56%+2.99% - - 359M
-1.55%+10.75%-58.06%+197.00% 247M
Average +0.14%+0.38%+18.32%+45.45% 2.47B
Weighted average by Cap. +0.31%-0.20%+12.21%-1.27%

Financials

2024 2025
Net sales 588K 506K 466K 437K 821K 55.52M 829K 5.51M 2.15M 27.19M 2.2M 2.16M 94.09M 461K 398K 366K 343K 645K 43.61M 651K 4.33M 1.69M 21.36M 1.73M 1.7M 73.9M
Net income -2.38M -2.05M -1.89M -1.77M -3.33M -225M -3.36M -22.31M -8.71M -110M -8.93M -8.74M -381M -10.6M -9.14M -8.41M -7.89M -14.82M -1B -14.97M -99.44M -38.84M -491M -39.79M -38.95M -1.7B
Net Debt 1.42M 1.23M 1.13M 1.06M 1.99M 135M 2.01M 13.36M 5.22M 65.92M 5.35M 5.23M 228M -1.14M -979K -901K -845K -1.59M -107M -1.6M -10.65M -4.16M -52.58M -4.26M -4.17M -182M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
26-06-15 1.790 $ 0.00% 5,193
26-06-12 1.790 $ -1.16% 2,626
26-06-11 1.811 $ -1.74% 15,404
26-06-10 1.843 $ -0.17% 315
26-06-09 1.846 $ -2.32% 24,033
  1. Stock Market
  2. Stocks
  3. POSC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!